Inhibitor Therapeutics, Inc. (INTI)
- Previous Close
0.0000 - Open
0.0373 - Bid 0.0342 x --
- Ask 0.0614 x --
- Day's Range
0.0373 - 0.0373 - 52 Week Range
0.0340 - 0.1080 - Volume
12,000 - Avg. Volume
20,286 - Market Cap (intraday)
9.65M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
inhibitortx.comRecent News: INTI
View MorePerformance Overview: INTI
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INTI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INTI
View MoreValuation Measures
Market Cap
9.65M
Enterprise Value
4.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.86
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.15%
Return on Equity (ttm)
-109.75%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-3.29M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
4.32M
Total Debt/Equity (mrq)
6.24%
Levered Free Cash Flow (ttm)
-2.26M